AICAR

Originally developed as a potential diabetes treatment, this nucleoside analog has gained attention in metabolic research for its ability to trigger cellular pathways typically activated during exercise. Researchers study it as a potential 'exercise pill' that could theoretically provide some metabolic benefits of physical activity through biochemical activation rather than muscle contraction.

The compound mimics cellular energy depletion by activating AMPK, a protein that acts like a cellular fuel gauge and metabolic switch. When AMPK senses low energy (or thinks it does), it triggers a cascade of changes: cells start burning more fat, increase glucose uptake, and ramp up mitochondrial production to meet perceived energy demands.